Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Boehringer Ingelheim
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
Seagen Inc.
Filamon LTD
Varian, a Siemens Healthineers Company
Novartis
PMV Pharmaceuticals, Inc
Pfizer
AstraZeneca
Novartis
Tomsk National Research Medical Center of the Russian Academy of Sciences
Region Jönköping County
Fred Hutchinson Cancer Center
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
Hoffmann-La Roche
University of Michigan Rogel Cancer Center
Rutgers, The State University of New Jersey
Eli Lilly and Company
AstraZeneca
BeOne Medicines
National Institutes of Health Clinical Center (CC)
University of Chicago
Bayer
Psyence Australia Pty Ltd
Convalife (Shanghai) Co., Ltd.
University of California, Irvine
Eastern Cooperative Oncology Group
ViroMissile, Inc.
University of California, Davis
Replimune Inc.
Terremoto Biosciences Inc.
Dana-Farber Cancer Institute
University Health Network, Toronto
Jazz Pharmaceuticals
Kaiser Permanente
Centre Antoine Lacassagne
Dana-Farber Cancer Institute
Carevive Systems, Inc.
University of Pennsylvania
Duke University
University Hospital, Lille
University of Florida
AstraZeneca
M.D. Anderson Cancer Center